Artera sells a metastatic prostate-cancer mortality estimate on a validation it has not disclosed

Artera and its commercial partner Tempus have launched a version of the ArteraAI Prostate test for men with metastatic hormone-sensitive prostate cancer (mHSPC). Artera bills it as “the first digital pathology-based prognostic test designed to help inform treatment planning” for that setting; Tempus uses narrower language, calling it the “first prostate digital pathology algorithm in the Tempus ecosystem available for clinical use” and the first externally developed one in that ecosystem. The test reads a digitized biopsy slide alongside clinical variables through the company’s multimodal AI (MMAI) model and returns, per Artera, “a patient-specific estimate of 5-year prostate cancer-specific mortality (PCSM) in patients treated with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI).”

The verifiable problem is what supports that specific number.

The marketed claim cites a validation the company does not disclose

For the marketed setting, Artera’s own release says the model “was further validated in patients with mHSPC receiving ADT plus ARPI as significantly prognostic for prostate cancer-specific mortality.” But none of the materials announcing the launch — Artera’s release or Tempus’s — name that validation’s trial or cohort, give its sample size, report a hazard ratio or confidence interval, or point to a peer-reviewed publication. A reader is asked to accept a PCSM estimate in ADT-plus-ARPI patients on the strength of a study whose existence is asserted but whose data and citation appear in none of these sources. Under a primary-source standard, that claim is unverifiable as published.

The peer-reviewed validation measured a different endpoint, in a different regimen

The one validation that is peer-reviewed and traceable is a separate analysis, published in European Urology Oncology, built on the phase 3 CHAARTED trial (NCT00309985). It does not match the marketed claim on two counts.

First, the endpoint. CHAARTED’s primary outcome was overall survival (OS), defined in the paper as “the time from randomization until death from any cause” — not the prostate cancer-specific mortality the product reports. Of 790 patients enrolled, 586 (74.2%) had evaluable digital pathology and 456 had the clinical data needed to generate MMAI scores. In that cohort the continuous MMAI score was associated with OS, the primary endpoint, with a hazard ratio of 1.51 per standard deviation (95% CI 1.33–1.73; p<0.001). Estimated 5-year overall survival was 83% in the MMAI-low group, 58% intermediate, and 39% high. The secondary outcomes were clinical progression and castration-resistant disease; prostate cancer-specific mortality was not reported as an outcome.

Second, the regimen. CHAARTED randomized men to ADT alone versus ADT plus docetaxel chemotherapy. There was no ARPI arm. The setting Artera markets — ADT plus an ARPI — is not the regimen in which this published model was tested.

Prognostic, not predictive

In the CHAARTED analysis, the data support sorting risk rather than guiding therapy. The authors reported “no statistically significant interaction between treatment and either continuous or categorical MMAI risk scores,” called the analysis underpowered, and state the model “did not predict for docetaxel benefit.” The score identifies who is likely to do worse; in this dataset it did not show which men benefit more from adding chemotherapy.

The peer-reviewed validation measured all-cause survival in a docetaxel trial. The cause-specific mortality, ADT-plus-ARPI claim the test is sold on rests on a separate validation for which the company names no trial, number, or citation.

The mHSPC test is offered as a laboratory-developed test, distinct from Artera’s localized-disease indication authorized by FDA via De Novo (DEN240068), which covers a 10-year distant-metastasis and prostate cancer-specific mortality risk estimate in treatment-naive, non-metastatic patients. Whether a mortality estimate shifts treatment in a metastatic setting where intensification is already standard remains an open clinical question — and one that the undisclosed ADT-plus-ARPI validation, if published with its endpoint, comparator, sample size, and effect size, would help answer. This is journalism, not medical advice.